Matthew Henn
Chief Tech/Sci/R&D Officer bij SERES THERAPEUTICS, INC.
Vermogen: 72 317 $ op 29-02-2024
Profiel
Matthew R.
Henn is Chief Scientific Officer & Executive VP at Seres Therapeutics, Inc.
In his past career Dr. Henn was Director-Viral Genomics at The Broad Institute, Inc.
He received a doctorate from the University of California, Berkeley and an undergraduate degree from the University of New Hampshire.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
SERES THERAPEUTICS INC
0.05% | 16-02-2024 | 63 436 ( 0.05% ) | 72 317 $ | 29-02-2024 |
Actieve functies van Matthew Henn
Bedrijven | Functie | Begin |
---|---|---|
SERES THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 07-02-2019 |
Eerdere bekende functies van Matthew Henn
Bedrijven | Functie | Einde |
---|---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01-06-2012 |
Viral Genomics, Inc. | Director/Board Member | - |
Opleiding van Matthew Henn
University of California, Berkeley | Doctorate Degree |
University of New Hampshire | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SERES THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Viral Genomics, Inc. | |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |